Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atripla Approved As First Once-Daily, Single-Tablet HIV Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

The Bristol/Gilead combination product will launch within seven business days.

You may also be interested in...



Gilead Quad’s Side Effects Profile, Novel Agents To Get Advisory Committee Review

FDA’s Antiviral Drugs Advisory Committee takes up the four-drug HIV-1 regimen, which includes two new agents, on May 11. The firm hopes to be able to sell the combination in part on its favorable side effects profile if the product is approved.

BMS, Gilead Atripla Alliance To Include European Commercialization

Merck & Co. gives up exclusive ex-U.S. rights to any product containing efavirenz in some European countries to allow the deal.

BMS, Gilead Atripla Alliance To Include European Commercialization

Merck & Co. gives up exclusive ex-U.S. rights to any product containing efavirenz in some European countries to allow the deal.

Related Content

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel